Phase 1 × Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative × Clear all
NCT04637009 2024-08-02

A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms

Astex Pharmaceuticals, Inc.

Phase 1 Terminated
20 enrolled
NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

OHSU Knight Cancer Institute

Phase 1 Terminated
2 enrolled
NCT00054236 2020-07-27

Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia

Case Comprehensive Cancer Center

Phase 1 Completed
55 enrolled
NCT00036790 2019-12-17

Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer

University of Wisconsin, Madison

Phase 1 Completed
NCT00039091 2018-09-05

Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 1 Terminated
26 enrolled
NCT01484015 2018-07-18

Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia

Wake Forest University Health Sciences

Phase 1 Completed
70 enrolled
NCT00006239 2017-09-29

Phenylbutyrate and Tretinoin in Treating Patients With Hematologic Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Completed
NCT00513474 2017-05-25

Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant

Massachusetts General Hospital

Phase 1 Completed
46 enrolled 11 charts
NCT00509691 2017-05-09

Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy

University of Louisville

Phase 1 Completed
20 enrolled
NCT00104975 2016-12-15

Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer

Yale University

Phase 1 Completed
20 enrolled
NCT00019656 2015-04-29

Perifosine in Treating Patients With Refractory Solid Tumors or Hematologic Cancer

National Cancer Institute (NCI)

Phase 1 Completed
NCT00351975 2014-12-23

Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases

National Cancer Institute (NCI)

Phase 1 Completed
56 enrolled
NCT01164163 2014-10-23

INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease

Children's Oncology Group

Phase 1 Completed
49 enrolled
NCT01231919 2014-04-29

MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia

National Cancer Institute (NCI)

Phase 1 Completed
45 enrolled
NCT00769613 2013-12-18

Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus Infections

National Cancer Institute (NCI)

Phase 1 Unknown
20 enrolled
NCT00049686 2013-07-18

VNP40101M in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome

National Cancer Institute (NCI)

Phase 1 Completed
NCT00064090 2013-07-18

3-AP and Cytarabine in Treating Patients With Hematologic Cancer

National Cancer Institute (NCI)

Phase 1 Completed
NCT00006040 2013-06-19

Radiolabeled Monoclonal Antibody Therapy and Etoposide Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Myelodysplastic Syndrome or Refractory Leukemia

Memorial Sloan Kettering Cancer Center

Phase 1 Completed
NCT00045006 2013-05-30

Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer

National Cancer Institute (NCI)

Phase 1 Completed
NCT00073944 2013-05-30

BCX-1777 in Treating Patients With Refractory Cancer

National Cancer Institute (NCI)

Phase 1 Completed
NCT00357305 2013-05-03

Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders

National Cancer Institute (NCI)

Phase 1 Completed
25 enrolled
NCT00060372 2013-03-27

Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer

National Cancer Institute (NCI)

Phase 1 Completed
21 enrolled
NCT00569283 2013-03-26

Donor Natural Killer Cell Infusion in Preventing Relapse or Graft Failure in Patients Who Have Undergone Donor Bone Marrow Transplant

National Cancer Institute (NCI)

Phase 1 Completed
18 enrolled
NCT00114257 2013-02-11

Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders

National Cancer Institute (NCI)

Phase 1 Completed
36 enrolled
NCT00004245 2013-01-18

Sodium Salicylate in Treating Patients With Advanced Myelodysplastic Syndrome, Acute Myelogenous Leukemia, or Chronic Lymphocytic Leukemia

Memorial Sloan Kettering Cancer Center

Phase 1 Completed
NCT00361049 2010-11-05

Donor Mesenchymal Stem Cell Infusion in Treating Patients With Acute or Chronic Graft-Versus-Host Disease After Undergoing a Donor Stem Cell Transplant

Case Comprehensive Cancer Center

Phase 1 Completed
49 enrolled
NCT00062140 2010-09-21

Total-Body Irradiation, Cyclophosphamide, and Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Fred Hutchinson Cancer Center

Phase 1 Completed
NCT00003243 2010-03-10

Combination Chemotherapy Plus Infusion of White Blood Cells in Treating Patients With Hematologic Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Completed
NCT00004871 2010-03-10

Azacitidine Plus Phenylbutyrate in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Completed
NCT00006042 2010-03-10

Cyclophosphamide Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Completed
NCT00015925 2010-03-10

MS-275 in Treating Patients With Hematologic Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Completed
NCT00004058 2010-01-26

12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder

Rutgers, The State University of New Jersey

Phase 1 Terminated